The estimated Net Worth of Marc Tessier Lavigne is at least 2.17 十億$ dollars as of 23 November 2022. Marc Lavigne owns over 20,000 units of Regeneron Pharmaceuticals stock worth over 2,134,917,856$ and over the last 13 years he sold REGN stock worth over 29,555,810$. In addition, he makes 699,993$ as Independent Director at Regeneron Pharmaceuticals.
Sign up
Marc Lavigne REGN stock SEC Form 4 insiders trading
Marc has made over 25 trades of the Regeneron Pharmaceuticals stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of REGN stock worth 609,600$ on 23 November 2022.
The largest trade he's ever made was selling 400,000 units of Regeneron Pharmaceuticals stock on 16 June 2020 worth over 10,440,000$. On average, Marc trades about 17,846 units every 60 days since 2011. As of 23 November 2022 he still owns at least 1,870,356 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Marc Lavigne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marc Tessier-Lavigne biography
Dr. Marc Tessier-Lavigne Ph.D. serves as Independent Director of the Company. He has been the President of Stanford University since 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc. Dr. Tessier-Lavigne’s distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led the board to conclude that Dr. Tessier-Lavigne should serve as a director.
What is the salary of Marc Lavigne?
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of Marc Lavigne at Regeneron Pharmaceuticals is 699,993$. There are 23 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of 22,304,300$.
How old is Marc Lavigne?
Marc Lavigne is 60, he's been the Independent Director of Regeneron Pharmaceuticals since 2011. There are 14 older and 7 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
What's Marc Lavigne's mailing address?
Marc's mailing address filed with the SEC is C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Regeneron Pharmaceuticals
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over 13,084,686,326$ worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth 2,539,854,760$ . The most active insiders traders include Sanofi、Pharma Ag Novartis、Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of 47,694,347$. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth 381,400$.
What does Regeneron Pharmaceuticals do?
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
What does Regeneron Pharmaceuticals's logo look like?
Complete history of Marc Lavigne stock trades at Agios Pharmaceuticals Inc、Regeneron Pharmaceuticals、Pfizer、Denali Therapeutics Inc
Regeneron Pharmaceuticals executives and stock owners
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include:
-
P. Roy Vagelos,
Chairman of the Board, Director -
Leonard Schleifer,
President, Chief Executive Officer, Director -
George Yancopoulos,
President, Chief Scientific Officer, Director -
Marion McCourt,
Senior Vice President - Commercial -
Andrew Murphy,
Executive Vice President - Research -
Neil Stahl,
Executive Vice President - Research and Development -
Robert Landry,
Chief Financial Officer, Executive Vice President - Finance -
Daniel Van Plew,
Executive Vice President, General Manager - Industrial Operations and Product Supply -
Dr. George D. Yancopoulos M.D., Ph.D.,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Dr. Leonard S. Schleifer M.D., Ph.D.,
Founder, Pres, CEO & Director -
Dr. George D. Yancopoulos,
Scientific Founder, Pres, Chief Scientific Officer & Director -
Robert E. Landry Jr.,
Exec. VP of Fin. & CFO -
Daniel P. Van Plew,
Exec. VP and GM of Industrial Operations & Product Supply -
Joseph J. LaRosa,
Exec. VP, Gen. Counsel & Sec. -
Dr. Andrew J. Murphy,
Exec. VP of Research -
Arthur Ryan,
Independent Director -
George Sing,
Independent Director -
Christine Poon,
Independent Director -
Michael Brown,
Independent Director -
Huda Zoghbi,
Independent Director -
Joseph Goldstein,
Independent Director -
Bonnie Bassler,
Independent Director -
N. Anthony Coles,
Independent Director -
Marc Tessier-Lavigne,
Independent Director -
Christopher Fenimore,
Vice President, Controller -
Joseph LaRosa,
Executive Vice President, General Counsel, Secretary -
Justin Holko,
VP of Investor Relations -
Bob McCowan,
Sr. VP of IT & Chief Information Officer -
Gerald Underwood,
Sr. VP of Technical Operations -
Christopher R. Fenimore,
Sr. VP, Head of Accounting & Controller -
Patrice Gilooly,
Sr. VP of Quality Assurance & Operations -
Charles A Baker,
Director -
Michael S Aberman,
SVP Strategy Investor Relation -
Sanofi,
-
Robert J Terifay,
EVP Commercial -
Alfred G Gilman,
Director -
Robert Alexander Ingram,
Director -
Eric M Shooter,
Director -
Murray A Goldberg,
SVP Administration & Asst Secr -
Stuart Kolinski,
SVP General Counsel and Secret -
Amerique Du Nord S.N.C. San...,
-
Peter Dworkin,
VP Investor Relations & Commun -
Randall Rupp,
SVP, Manufuring Operations -
Pharma Ag Novartis,
10% owner -
Hans Peter Guler,
VP Clinical Programs -
William Roberts,
VP Reg Dev & Med Safety -
Peter Powchik,
SVP Clinical Development & Reg -
Douglas S Mc Corkle,
VP Controller and Asst Treasur -
Craig B. Thompson,
Director -
Kathryn Guarini,
Director -
David P Schenkein,
Director -
Jason Pitofsky,
VP Controller